Market capitalization | $5.00m |
Enterprise Value | $2.54m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 254.00 |
P/S ratio (TTM) P/S ratio | 500.00 |
P/B ratio (TTM) P/B ratio | 1.32 |
Revenue growth (TTM) Revenue growth | -99.79% |
Revenue (TTM) Revenue | $10.00k |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
2 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:
2 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -35 -35 |
7%
7%
|
|
Depreciation and Amortization | 2.32 2.32 |
16%
16%
|
|
Stock Compensation | 2.80 2.80 |
21%
21%
|
|
Operating Cash Flow | -30 -30 |
3%
3%
|
|
Investments | 0.20 0.20 |
9%
9%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -30 -30 |
3%
3%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline include Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
Head office | United States |
CEO | Dale Hogue |
Employees | 1 |
Founded | 2003 |
Website | www.alaunos.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.